Nike’s Importation Fine Serves As A Lesson For Drug Firms In China
This article was originally published in PharmAsia News
Executive Summary
Beijing issued Nike a RMB 4.87 million fine for using double standards for an imported product in China, prompting legal and industry watchers to warn multinational companies to keep prices competitive or they could find themselves under tighter scrutiny.